Q2 2024 Earnings Forecast for CEL-SCI Co. Issued By Zacks Small Cap (NYSE:CVM)

CEL-SCI Co. (NYSE:CVM) – Stock analysts at Zacks Small Cap issued their Q2 2024 EPS estimates for shares of CEL-SCI in a report issued on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten forecasts that the company will earn ($0.14) per share for the quarter. The consensus estimate for CEL-SCI’s current full-year earnings is ($0.48) per share. Zacks Small Cap also issued estimates for CEL-SCI’s Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.11) EPS and FY2026 earnings at ($0.24) EPS.

Separately, StockNews.com downgraded shares of CEL-SCI from a “hold” rating to a “sell” rating in a report on Friday, March 15th.

CEL-SCI Stock Down 4.4 %

CVM stock opened at $1.52 on Tuesday. The company has a market cap of $82.05 million, a price-to-earnings ratio of -2.24 and a beta of 1.29. The company has a 50 day moving average of $2.06 and a two-hundred day moving average of $2.18. The company has a quick ratio of 0.78, a current ratio of 1.26 and a debt-to-equity ratio of 0.75. CEL-SCI has a 12-month low of $1.04 and a 12-month high of $3.23.

CEL-SCI (NYSE:CVM) last issued its quarterly earnings results on Wednesday, February 14th. The company reported ($0.14) EPS for the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Lincoln National Corp lifted its holdings in shares of CEL-SCI by 138.2% during the 3rd quarter. Lincoln National Corp now owns 55,545 shares of the company’s stock worth $69,000 after acquiring an additional 32,225 shares during the period. Cutter & CO Brokerage Inc. lifted its holdings in CEL-SCI by 20.5% during the 3rd quarter. Cutter & CO Brokerage Inc. now owns 102,845 shares of the company’s stock valued at $129,000 after purchasing an additional 17,500 shares during the last quarter. Black Diamond Financial LLC lifted its holdings in CEL-SCI by 20.5% during the 3rd quarter. Black Diamond Financial LLC now owns 53,000 shares of the company’s stock valued at $66,000 after purchasing an additional 9,000 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in CEL-SCI by 195.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 8,280 shares of the company’s stock valued at $37,000 after purchasing an additional 5,474 shares during the last quarter. Finally, MML Investors Services LLC bought a new position in shares of CEL-SCI in the third quarter worth about $31,000. 12.08% of the stock is currently owned by institutional investors and hedge funds.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.